

Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waiver under 18 U.S.C. § 208(b)(3) and 21 U.S.C. §355 (n)(4)

Peter Gross, M.D.

Committee: Anti-Infective Drugs Advisory Committee

Meeting Date: September 12, 2006

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to new drug application (NDA) 21-158/S-006, Factive (gemifloxacin mesylate) tablets, Licensed from LG Life Sciences, Ltd., marketed by Oscient Pharmaceuticals Corporation, for the proposed treatment of acute bacterial sinusitis, I am eligible to receive waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. §355 (n)(4).

Type of Interest	Nature	Magnitude
Stock	Competitor	Valued from \$5,001 to \$25,000
Unrelated Consulting	Competitor	Less than \$10,001

I hereby request that FDA make this information publicly available on my behalf at the start of the advisory committee meeting for which it is issued. The public disclosure will be accomplished by reading the statement into the record and by making a written copy publicly available at the time of the meeting. I understand that without public disclosure of these interests, the waivers are not valid.

151
Signature of SGE

8/16/06
Date